https://scholars.lib.ntu.edu.tw/handle/123456789/523507
標題: | Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma | 作者: | Chang, Y.-H. CHUNG-MING CHEN Chen, H.-Y. PAN-CHYR YANG |
公開日期: | 2015 | 出版社: | Nature Publishing Group | 卷: | 5 | 起(迄)頁: | 10979 | 來源出版物: | Scientific Reports | 摘要: | Lung adenocarcinoma is often diagnosed at an advanced stage with poor prognosis. Patients with different clinical outcomes may have similar clinico-pathological characteristics. The results of previous studies for biomarkers for lung adenocarcinoma have generally been inconsistent and limited in clinical application. In this study, we used inverse-variance weighting to combine the hazard ratios for the four datasets and performed pathway analysis to identify prognosis-associated gene signatures. A total of 2,418 genes were found to be significantly associated with overall survival. Of these, a 21-gene signature in the HMGB1/RAGE signalling pathway and a 31-gene signature in the clathrin-coated vesicle cycle pathway were significantly associated with prognosis of lung adenocarcinoma across all four datasets (all p-values<0.05, log-rank test). We combined the scores for the three pathways to derive a combined pathway-based risk (CPBR) score. Three pathway-based signatures and CPBR score also had more predictive power than single genes. Finally, the CPBR score was validated in two independent cohorts (GSE14814 and GSE13213 in the GEO database) and had significant adjusted hazard ratios 2.72 (p-value<0.0001) and 1.71 (p-value<0.0001), respectively. These results could provide a more complete picture of the lung cancer pathogenesis. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930676348&doi=10.1038%2fsrep10979&partnerID=40&md5=fc409fab0998a6d4cabe931d6828d55c https://scholars.lib.ntu.edu.tw/handle/123456789/523507 |
ISSN: | 2045-2322 | DOI: | 10.1038/srep10979 | SDG/關鍵字: | advanced glycation end product receptor; beta adrenergic receptor; high mobility group B1 protein; transcriptome; adenocarcinoma; clathrin-coated vesicle; cohort analysis; gene expression profiling; gene expression regulation; genetics; human; Kaplan Meier method; lung tumor; metabolism; mortality; non small cell lung cancer; outcome assessment; pathology; prognosis; proportional hazards model; reproducibility; signal transduction; Adenocarcinoma; Advanced Glycosylation End Product-Specific Receptor; Carcinoma, Non-Small-Cell Lung; Clathrin-Coated Vesicles; Cohort Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Kaplan-Meier Estimate; Lung Neoplasms; MAP Kinase Signaling System; Patient Outcome Assessment; Prognosis; Proportional Hazards Models; Receptors, Adrenergic, beta; Reproducibility of Results; Signal Transduction; Transcriptome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。